

Hepatitis C in Primary Care and Drug and Alcohol Settings Education Program

FRANCE October 2019 Summary

Following the success of workshops in late 2018 and early 2019, the *Hepatitis C in Primary Care and Drug and Alcohol Settings* education program continued in October across France. Five workshops were delivered, including one adjacent to the *Colloque ATHS Biarritz* to maximise reach to the target audience.

With the changes to HCV direct-acting antiviral (DAA) prescription in May 2019, response to the Program has been even more positive with physicians working in general practices and alcohol and other drug settings enthusiastic about providing treatment in their own setting. There has also been an increase in nurses attending from CSAPA and CAARUD services.



5
Workshops



87
Attendees


Locations

- Biarritz
- Bordeaux
- Nice
- Lille
- Paris




Participant Demographics

Profession



Workplace Setting



*AOD – alcohol and other drugs

Knowledge

Participants responded to a set of 10 questions in surveys that measured knowledge in HCV transmission, testing, treatment and care. The same set of questions are asked before and after the workshop, demonstrating an improvement in participant scores.

Average Scores /10

7.6
Pre-Course



9.5
Post-Course


Confidence

Participants self-reported confidence prior to completing the training and immediately post training in the key-program competencies. The below shows those reporting confident or very confident.


Educate patients about the risk factors and prevention of HCV



Ensure people at risk of HCV are regularly screened



Advise patients about the latest therapies for HCV



Interpret test results and diagnose HCV



Assess or recognise severity of liver disease



Treat HCV and manage side effects




Educate clinical staff about HCV and serve as point of contact for questions/issues




Learning Objectives


Participants were asked following the workshops to rate the extent to which each of the five Program learning objectives were met. The below depicts the proportion indicating each was entirely met.



1. Describe the risk factors for HCV infection enabling effective screening and prevention education.




2. Demonstrate competence conducting and interpreting test to diagnose HCV.



3. Recognise risk factors, clinical signs, symptoms and complications of liver disease.



4. Demonstrate understanding of DAA therapy for the treatment of HCV and competence in selecting appropriate therapy.



5. Describe recommended on-treatment monitoring and post-treatment follow up protocols.

How will the Program change your practice?

« Pouvoir initier et surveiller le traitement des hépatites C dans le cadre du parcours simplifié. Augmenter le dépistage et diminuer les perdus de vue. »

« Je peux aujourd'hui informer, accompagner et soutenir les personnes dans leur démarche de soins, de façon adaptée. »

Conclusions

As in 2018, there was a clear increase in confidence across all Program competencies, as well as an overall satisfaction that learning objectives were met.

This suggests that as all doctors in France can now prescribe HCV DAA treatment following the AFEF's simplified pathway, we can hope to see course participants beginning to prescribe in their practices.